Clinical Trials

Will Otsuka's Acquisition of Jnana Transform Drug Discovery for PKU?
Research & Development Will Otsuka's Acquisition of Jnana Transform Drug Discovery for PKU?

The acquisition of Jnana Therapeutics by Otsuka Pharmaceutical for $800 million in cash marks a significant moment in the pharmaceutical industry. This bold move grants Otsuka access to Jnana's innovative drug discovery platform, along with their experimental medicine for treating

How Will Jim Wilson’s Exit from UPenn Impact Gene Therapy?
Research & Development How Will Jim Wilson’s Exit from UPenn Impact Gene Therapy?

Jim Wilson, a seminal figure in the field of gene therapy, is departing the University of Pennsylvania (UPenn) after an illustrious career spanning decades. His decision to step down marks a significant juncture for both the institution and the broader gene therapy landscape. Over the years, Wilson

Can ZMA001 Revolutionize PAH Treatment With FDA Orphan Drug Designation?
Research & Development Can ZMA001 Revolutionize PAH Treatment With FDA Orphan Drug Designation?

Pulmonary arterial hypertension (PAH) is a debilitating and life-threatening condition characterized by the blockage and narrowing of pulmonary arterioles. Current treatment options primarily focus on symptomatic relief, especially through the use of vasodilators. These medications help widen blood

FDA Approves Leqselvi for Severe Alopecia Areata, A JAK Inhibitor
Research & Development FDA Approves Leqselvi for Severe Alopecia Areata, A JAK Inhibitor

The FDA's recent approval of a new treatment for severe alopecia areata marks a significant advance in addressing this challenging condition. Deuruxolitinib, branded as Leqselvi and developed by Sun Pharmaceutical Industries, will now compete with existing treatments from Eli Lilly and Pfizer,

Cartesian’s Descartes-08 Shows Promise in Myasthenia Gravis; Market Wary
Research & Development Cartesian’s Descartes-08 Shows Promise in Myasthenia Gravis; Market Wary

The field of autoimmune disease treatment is witnessing groundbreaking innovations, with Cartesian Therapeutics making headlines for its latest Phase 2 clinical trial results of Descartes-08. This experimental cell therapy aims to bring hope to patients suffering from myasthenia gravis, a rare and

Artiva’s $167M IPO Signals Shift to Allogeneic Therapies for Autoimmune Diseases
Research & Development Artiva’s $167M IPO Signals Shift to Allogeneic Therapies for Autoimmune Diseases

Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later